Furthermore, three important clinical studies using two different genomic assays recently demonstrated premenopausal patients or patients aged ≤ 50 years with HR-positive/HER2-negative (HR+/HER2−), low genomic risk breast cancer exhibit a chemotherapy benefit. Here, ERBB2 is linked to breast carcinoma.